title: Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation.
authors.forename: M H
authors.initials: MH
authors.lastname: Qazilbash
authors.forename: N T
authors.initials: NT
authors.lastname: Ueno
authors.forename: C
authors.initials: C
authors.lastname: Hosing
authors.forename: M
authors.initials: M
authors.lastname: De Lima
authors.forename: J
authors.initials: J
authors.lastname: Cortes
authors.forename: A
authors.initials: A
authors.lastname: Massaro
authors.forename: Z
authors.initials: Z
authors.lastname: Rivera
authors.forename: M
authors.initials: M
authors.lastname: Deavers
authors.forename: J A
authors.initials: JA
authors.lastname: Adachi
authors.forename: R E
authors.initials: RE
authors.lastname: Champlin
mesh_terms: D000871:Anthelmintics / Q000627:therapeutic use; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D007559:Ivermectin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D013322:Strongyloidiasis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013827:Thiabendazole / Q000627:therapeutic use; D014184:Transplantation, Homologous
chemical_list: D000871:Anthelmintics; D007559:Ivermectin; D013827:Thiabendazole